Sinalização JAK/STAT
Os inibidores da sinalização JAK/STAT são compostos que interrompem a via da Janus quinase (JAK) e do transdutor e ativador da transcrição (STAT), que está envolvida na sinalização de citocinas, crescimento celular e resposta imunológica. Esses inibidores são ferramentas importantes para estudar a regulação dessa via e seu papel em diversas doenças, incluindo cânceres, distúrbios imunológicos e condições inflamatórias. Os inibidores de JAK/STAT também estão sendo desenvolvidos como terapias direcionadas para essas doenças. Na CymitQuimica, oferecemos uma ampla seleção de inibidores de sinalização JAK/STAT de alta qualidade para apoiar sua pesquisa em biologia molecular, oncologia e imunologia.
Subcategorias de "Sinalização JAK/STAT"
Foram encontrados 321 produtos de "Sinalização JAK/STAT"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
WDR5-IN-6
CAS:<p>WDR5-IN-6 is a WDR5 inhibitor targeting the WBM locus.WDR5-IN-6 is highly synergistic with OICR-9429, a WDR5 inhibitor that targets the WIN locus.WDR5-IN-6</p>Fórmula:C13H8Cl2N2O2SPureza:99.69%Cor e Forma:SoildPeso molecular:327.19Gusacitinib
CAS:<p>Gusacitinib (ASN-002) (ASN-002) is spleen tyrosine kinase (SYK) and janus kinase (JAK) inhibitor (IC50: 5-46 nM).</p>Fórmula:C24H28N8O2Pureza:98.06% - 99.94%Cor e Forma:SolidPeso molecular:460.53Nimucitinib
CAS:<p>Nimucitinib is a Janus kinase (JAK) inhibitor that can be used to treat dry eye and promote tear production.</p>Fórmula:C25H26F2N6O2Pureza:98.71%Cor e Forma:SoildPeso molecular:480.51Ilginatinib
CAS:<p>Ilginatinib (NS-018) is a highly active and orally bioavailable inhibitor of JAK2.</p>Fórmula:C21H20FN7Pureza:98.4% - 99.01%Cor e Forma:SolidPeso molecular:389.43TAK-901
CAS:<p>TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others</p>Fórmula:C28H32N4O3SPureza:99.02% - 99.59%Cor e Forma:SolidPeso molecular:504.64KT-333
CAS:<p>KT-333 is a potent, highly selective, heterobifunctional degrader of STAT3 for the treatment of a variety of STAT3-dependent pathologies, antitumor.</p>Fórmula:C60H74ClN10O14PSPureza:98.12%Cor e Forma:SolidPeso molecular:1257.78JAK2 Inhibitor V
CAS:<p>JAK2 Inhibitor V (JAK2 Inhibitor V Z3) is a novel specific inhibitor of Jak2, inhibiting Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner.</p>Fórmula:C23H24N2OPureza:98.36% - 99.15%Cor e Forma:SolidPeso molecular:344.45Pim-1 kinase inhibitor 8
CAS:<p>Pim-1 kinase inhibitor 8 is a Pim-1 kinase inhibitor with anticancer activity that inhibits cell migration and can be studied in breast cancer.</p>Fórmula:C14H17N3O3Pureza:99.81%Cor e Forma:SoildPeso molecular:275.3Golidocitinib
CAS:<p>Golidocitinib (AZD4205) is a selective JAK1 inhibitor (IC50: 73 nM) and weakly inhibits JAK2/JAK3 (IC50: >14.7, >30 μM).</p>Fórmula:C25H31N9O2Pureza:98.87% - 99.88%Cor e Forma:SolidPeso molecular:489.57N-(3-Aminopropyl)cyclohexylamine
CAS:<p>N-(3-Aminopropyl)cyclohexylamine inhibits spermine synthase; used in neuro disease research.</p>Fórmula:C9H20N2Pureza:98.05% - 98.82%Cor e Forma:Pale Yellow Clear LiquidPeso molecular:156.2685Ilginatinib maleate
CAS:<p>Ilginatinib maleate (NS-018 maleate) is a highly active and orally bioavailable inhibitor of JAK2.</p>Fórmula:C25H24FN7O4Pureza:99.74% - 99.82%Cor e Forma:SolidPeso molecular:505.5Uzansertib phosphate
CAS:<p>Uzansertib phosphate (INCB053914 phosphate) is an orally active, ATP-competitive inhibitor of pan-PIM kinase, inhibiting PIM1, PIM2 and PIM3.</p>Fórmula:C26H29F3N5O7PPureza:99.75% - 99.79%Cor e Forma:SolidPeso molecular:611.51Delgocitinib
CAS:<p>Delgocitinib is a potent JAK inhibitor (IC50: 2.8-58 nM), treats inflammatory diseases, and is the first topical drug for atopic dermatitis.</p>Fórmula:C16H18N6OPureza:99.95%Cor e Forma:SolidPeso molecular:310.35Brepocitinib P-Tosylate
CAS:<p>Brepocitinib P-Tosylate (PF-06700841 P-Tosylate) is a potent dual inhibitor of Janus kinase 1 (JAK1) and TYK2 (IC50s of 17 nM and 23 nM, respectively).</p>Fórmula:C25H29F2N7O4SPureza:99.82% - 99.97%Cor e Forma:SolidPeso molecular:561.6Bromisoval
CAS:<p>Bromisoval (Isobromyl) is a mild hypnotic and sedative with potential toxicity.</p>Fórmula:C6H11BrN2O2Pureza:98.86%Cor e Forma:SolidPeso molecular:223.07Ilginatinib hydrochloride
CAS:<p>Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable inhibitor of JAK2.</p>Fórmula:C21H21ClFN7Pureza:99.55%Cor e Forma:SolidPeso molecular:425.89AK-2292
<p>AK-2292: potent STAT5 PROTAC degrader, DC50 0.10 μM, degrades STAT5A/B, may shrink leukemia tumors in mice.</p>Fórmula:C52H54F2N7O10PS2Cor e Forma:SolidPeso molecular:1070.13LH168
<p>LH168 is a potent and selective probe for WDR5, with a SPR Kd value of 13 nM.</p>Fórmula:C29H31F3N6O2SCor e Forma:SolidPeso molecular:584.66SJ10542
CAS:<p>SJ10542: potent JAK2/3-targeting PG-PROTAC; DC50s: JAK2 - 14 nM, JAK3 - 11 nM, JAK2-fusion ALL - 24 nM; CRBN recruiter.</p>Fórmula:C41H46N12O5SCor e Forma:SolidPeso molecular:818.95PM-81I
CAS:<p>PM-81I: Potent STAT6 inhibitor for allergic and pulmonary conditions, cancer research. Reduces STAT6 phosphorylation.</p>Fórmula:C43H58F2N3O10PCor e Forma:SolidPeso molecular:845.91Pumecitinib
CAS:<p>Pumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib exhibits anti-inflammatory activity.</p>Fórmula:C17H20N8O2SPureza:99.94%Cor e Forma:SoildPeso molecular:400.46TYD-68
<p>TYD-68 is a potent and selective CRBN-recruiting TYK2 PROTAC degrader, with a DC50 value of 0.42 nM. This compound effectively inhibits IL-12 and IFN-α-induced phosphorylation of STAT4 and STAT1, thereby blocking TYK2-dependent signaling pathways. TYD-68 is applicable in psoriasis research.</p>Cor e Forma:Odour SolidJAK-2/3-IN-1
CAS:<p>JAK-2/3-IN-1 inhibits JAK-2/3 isoforms with sub-250 nM Ki; from US patent US8163732B2.</p>Fórmula:C20H12ClN3OCor e Forma:SolidPeso molecular:345.79KT-333 diammonium
CAS:<p>KT-333 diammonium functions as a molecular glue that targets and degrades the STAT3 protein. It selectively mediates the degradation of STAT3 via the ubiquitin-proteasome pathway by attaching to STAT3 and the E3 ubiquitin ligase von Hippel-Lindau protein (VHL). This compound exhibits strong specificity in degrading STAT3 and demonstrates significant antitumor activity. KT-333 diammonium is applicable in researching hematologic malignancies, including large granular lymphocytic leukemia (LGL-L), peripheral T-cell lymphoma (PTCL), and cutaneous T-cell lymphoma (CTCL).</p>Fórmula:C60H80ClN12O14PSCor e Forma:SolidPeso molecular:1291.84JAK-IN-29
<p>JAK-IN-29 (Compound 3) is a potent inhibitor of Janus kinases (JAK) [1].</p>Fórmula:C17H14ClN5O2Pureza:98%Cor e Forma:SolidPeso molecular:355.78Deuruxolitinib
CAS:<p>Deuruxolitinib functions as an inhibitor of JAK1/2.</p>Fórmula:C17H18N6Cor e Forma:SolidPeso molecular:314.41MR44397
<p>MR44397 is a ligand for WD40 repeat (WDR) 5 and is applicable in cancer research.</p>Fórmula:C23H26N4O2SCor e Forma:SolidPeso molecular:422.54JAK-IN-33
<p>JAK-IN-33 (Compound 3 (R)) is a selective inhibitor of the Janus kinase (JAK) family [1].</p>Pureza:98%Cor e Forma:Odour SolidSJ1008030
CAS:<p>SJ1008030, a JAK2 PROTAC, degrades JAK2; EC50: 5.4 nM, IC50: 32.09 nM in MHH-CALL-4 cells for leukemia research.</p>Fórmula:C42H43N13O7SCor e Forma:SolidPeso molecular:873.94JI069
CAS:<p>JI069 (WAY-354189) is a potent STAT3 inhibitor that inhibits gp130 signaling by inducing dissociation between gp130 and JAK1.</p>Fórmula:C15H12Cl2N2O4SPureza:98.01%Cor e Forma:SolidPeso molecular:387.24Tyk2-IN-22
CAS:<p>Tyk2-IN-22 (Compound A8) is a selective inhibitor of tyrosine kinase 2 (Tyk2), effectively inhibiting Tyk2, JAK1, and JAK3 with IC50 values of 9.7 nM, 148.6 nM, and 883.3 nM, respectively. Additionally, Tyk2-IN-22 suppresses downstream STAT5 phosphorylation.</p>Fórmula:C16H16ClN5O2Cor e Forma:SolidPeso molecular:345.78HAT-SIL-TG-1&AT
<p>HAT-SIL-TG-1&AT: a hypoxia-activated JAK inhibitor that curbs HEL cell growth & STAT3/5 phosphorylation in tumors.</p>Fórmula:C60H69N17O11SCor e Forma:SolidPeso molecular:1236.36TYK2 activator-1
<p>TYK2activator-1 (16b) is a TYK2 activator with an EC50 value of 1.78 μM. It inhibits JAK2 and JAK3 with IC50 values of 6.8 μM and 6.3 μM, respectively.</p>Fórmula:C23H21FN4O2Cor e Forma:SolidPeso molecular:404.16485Fulipiftide
CAS:<p>Fulipiftide is a short peptide derived from pigment epithelium-derived factor (PEDF). It stimulates the amplification of nuclear stem cell factor+TSPC by activating the ERK2 and STAT3 signaling pathways. Fulipiftide also exhibits anti-inflammatory properties and is applicable in research on acute tendon injuries.</p>Fórmula:C144H227N41O47Cor e Forma:SolidPeso molecular:3284.59DBL-6-13
<p>DBL-6-13 is an inhibitor of WDR5, displaying moderate binding affinity with dissociation constants (Kd) of 6.8 μM and 9.1 μM as determined by microscale thermophoresis analysis and fluorescence polarization analysis, respectively.</p>Fórmula:C25H38N4O3Cor e Forma:SolidPeso molecular:442.59Eflepedocokin alfa
CAS:<p>Eflepedocokin alfa is a recombinant IL-22/IgG2-Fc protein, potentially protecting cells and enhancing immune function and tissue repair.</p>Cor e Forma:LiquidPROTAC TYK2 degradation agent1
CAS:<p>PROTAC TYK2 Agent1 selectively degrades TYK2, with a 14 nM DC50, for autoimmune research.</p>Fórmula:C55H69N13O7SPureza:98%Cor e Forma:SolidPeso molecular:1056.28AS2553627
CAS:<p>AS2553627 is a JAK inhibitor. AS2553627 prevents chronic rejection in rat cardiac allografts.</p>Fórmula:C18H19N5OCor e Forma:SolidPeso molecular:321.38SD-2301
CAS:<p>SD-2301 is a PROTAC degrader of STAT3.</p>Fórmula:C64H80N13O15PS2Cor e Forma:SolidPeso molecular:1366.50STAT4-IN-1
<p>STAT4-IN-1 is a STAT4 inhibitor with a Ki of 0.35 μM. It holds promise for research into autoimmune diseases, including inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, and diabetes.</p>Cor e Forma:Odour SolidAxltide
CAS:<p>Axltide mimics mouse Insulin receptor substrate 1, amino acids 979-989 with sequence KKSRGDYMTMQIG.</p>Fórmula:C63H107N19O20S2Pureza:98%Cor e Forma:SolidPeso molecular:1514.77SJ1008030 formic
<p>SJ1008030 (compound 8) formic is a selective JAK2 degrader within the PROTAC class, demonstrating efficacy in inhibiting MHH-CALL-4 leukemia cell growth with an</p>Fórmula:C43H45N13O9SPureza:98%Cor e Forma:SolidPeso molecular:919.96Neocucurbitacin A
CAS:<p>Neocucurbitacin A (compound 7), a STAT3 inhibitor extracted from the pericarp of Aquilaria crassna, serves as a potential agent for anticancer research [1].</p>Fórmula:C31H42O8Pureza:98%Cor e Forma:SolidPeso molecular:542.66JAK2-IN-6
CAS:<p>JAK2-IN-6: A potent JAK2-specific inhibitor (IC50=22.86μg/mL), blocks JAK2 signaling, has anticancer properties, and is inactive against JAK1/3.</p>Fórmula:C14H10ClN3OS2Pureza:99.64%Cor e Forma:SolidPeso molecular:335.83JAK-IN-15
CAS:<p>JAK-IN-15 is a JAK inhibitor. WO2016119700A1 (Compound 15).</p>Fórmula:C22H23FN4O3SCor e Forma:SolidPeso molecular:442.51CMD178
<p>CMD178 is an important polypeptide that consistently reduces the expression of Foxp3 and STAT5 by inhibiting the IL-2/s IL-2Rα signaling pathway.</p>Fórmula:C46H59N9O7Pureza:98%Cor e Forma:SolidPeso molecular:850.03SJ988497
CAS:<p>SJ988497: PROTAC JAK2 degrader, inhibits CRLF2r cell growth, degrades GSPT1, combines Ruxolitinib, linker, Pomalidomide; researched for ALL.</p>Fórmula:C36H36N10O5Cor e Forma:SolidPeso molecular:688.74Povorcitinib phosphate
CAS:<p>Povorcitinib phosphate is a selective JAK1 inhibitor and can be used in studies about the treatment of cutaneous lupus erythematosus and Lichen planus.</p>Fórmula:C23H25F5N7O5PPureza:99.57%Cor e Forma:SolidPeso molecular:605.45APTSTAT3-9R
<p>APTSTAT3-9R-9R blocks STAT3 (Ki: 231 nmol/L), hindering cancer cell growth and resistance.</p>Fórmula:C223H330N80O51Pureza:98%Cor e Forma:SolidPeso molecular:4947.51JAK3-IN-15
<p>JAK3-IN-15 (compound 22) is a JAK3 inhibitor that reduces the secretion of p-JAK3 induced by LPS. It is utilized in research for rheumatoid arthritis.</p>Cor e Forma:Odour SolidSTAT3 degrader-1
CAS:<p>STAT3 Degrader-1 (Compound 295) is a potent degrader of STAT3, utilized in anticancer research [1].</p>Fórmula:C58H63F5N9O12PSCor e Forma:SolidPeso molecular:1236.2JAK1/TYK2-IN-1
CAS:<p>JAK1/TYK2-IN-1 is a dual inhibitor of TYK2 and JAK1 ( IC 50 = 29 and 41 nM respectively).</p>Fórmula:C18H20F3N7OCor e Forma:SolidPeso molecular:407.401KT-333 ammonium
CAS:<p>KT-333 ammonium (Compound A) acts as a molecular glue that targets and promotes the degradation of the STAT3 protein through the ubiquitin-proteasome system. This compound achieves selective degradation by binding simultaneously to the STAT3 protein and the E3 ubiquitin ligase von Hippel-Lindau protein (VHL). It exhibits strong selectivity and efficacy in degrading STAT3, possessing notable antitumor properties. KT-333 ammonium is particularly useful for research on hematologic malignancies, including large granular lymphocytic leukemia (LGL-L), peripheral T-cell lymphoma (PTCL), and cutaneous T-cell lymphoma (CTCL) [1].</p>Fórmula:C60H77ClN11O14PSCor e Forma:SolidPeso molecular:1274.81WDR5 ligand 2
CAS:<p>WDR5ligand 2 is a ligand for WDR5 and can be utilized in the synthesis of PROTAC WDR5degrader 1.</p>Fórmula:C29H31F3N4O4Cor e Forma:SolidPeso molecular:556.576JAK-STAT Compound Library
<p>A unique collection of 252 JAK/STAT signaling targeted compounds for high throughput and high content screening;</p>Cor e Forma:Odour SolidTyrosine Kinase Inhibitor Library
<p>A unique collection of 1016 tyrosine kinase inhibitors for high throughput screening and high content screening for drug discovery in tyrosine kinase related</p>Cor e Forma:Odour SolidKinase Inhibitor Library
<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>Cor e Forma:Odour SolidVB1080
<p>VB1080 (compound 12) is a potent PIM inhibitor with IC50 values of 69.5 µM for PIM1, 4996 µM for PIM2, and 9.88 µM for PIM3. Additionally, VB1080 exhibits cytotoxic properties and possesses anthelmintic activity.</p>Fórmula:C27H27N3O3Cor e Forma:SolidPeso molecular:441.522S-Ruxolitinib
CAS:<p>S-Ruxolitinib can be used in related research in the field of life sciences. Its product number is T3066 and CAS number is 1160597-27-2.</p>Fórmula:C17H18N6Pureza:98%Cor e Forma:SolidPeso molecular:306.37R8-T198wt
CAS:<p>Cell-permeable peptide blocking Pim-1 kinase, halts DU145 cell growth, causes G1 arrest and apoptosis, inert to RPWE-1 cells at 10-20 μM.</p>Fórmula:C111H211N59O26SPureza:98%Cor e Forma:SolidPeso molecular:2820.33OSM-SMI-10B
<p>OSM-SMI-10B, a variant of OSM-SMI-10, inhibits OSM-induced STAT3 activation in cancer cells.</p>Fórmula:C21H14O7Cor e Forma:SolidPeso molecular:378.33JAK2-IN-10
CAS:<p>JAK2-IN-10 (compound 5) is a potent inhibitor of JAK2v617f, with an IC50 value of ≤10 nM.</p>Fórmula:C33H33D3FN9O2Cor e Forma:SolidPeso molecular:612.71JAK/HDAC-IN-4
<p>JAK/HDAC-IN-4 (compound 11 i) is a dual inhibitor targeting both JAK2 and HDAC6, with IC50 values of 0.49 nM and 12 nM respectively. It inhibits cell proliferation and the production of nitric oxide. In a mouse model induced by Imiquimod, JAK/HDAC-IN-4 ameliorates psoriasiform skin lesions with low toxicity.</p>Fórmula:C30H32N8O5SCor e Forma:SolidPeso molecular:616.69FDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Cor e Forma:LiquidTyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9)
CAS:<p>Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide derived from mouse JAK2, specifically composed of amino acids 475 to 491.</p>Fórmula:C88H138N20O34P2Pureza:98%Cor e Forma:SolidPeso molecular:2082.1TP-5801 TFA
<p>TP-5801 TFA is an orally active inhibitor of TNK1, a non-receptor tyrosine kinase, with an IC50 value of 1.40 nM, demonstrating anti-tumor activity [1].</p>Fórmula:C26H32BrF3N8O3Pureza:98%Cor e Forma:SolidPeso molecular:641.48PROTAC STAT3 degrader-2
CAS:<p>PROTAC STAT3 degrader-2 selectively breaks down STAT3 (DC50: 3.54μM, Molm-16) with cancer research potential.</p>Fórmula:C59H60F2N9O13PCor e Forma:SolidPeso molecular:1172.13Pim-1 kinase inhibitor 11
<p>Pim-1 kinase inhibitor 11 (10f) is an inhibitor of PIM-1 with an IC50 value of 0.18 μM. It exhibits anticancer activity by inducing apoptosis and causing cell cycle arrest.</p>Cor e Forma:Odour SolidSTAT5-IN-3
<p>STAT5-IN-3 (Compound 14a) is a STAT5 inhibitor with anticancer properties. It works by blocking the tyrosine phosphorylation of STAT5A/5B at the Y694/699 sites, significantly reducing the expression of the STAT5B protein. This leads to the inhibition of downstream gene transcription, thereby preventing the proliferation and survival of leukemia cells. Additionally, STAT5-IN-3 has significant potential in overcoming chemotherapy resistance.</p>Fórmula:C25H27N5OCor e Forma:SolidPeso molecular:413.51JAK1/STAT3-IN-1
<p>JAK1/STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1/STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1/STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1/JAK1 and p-STAT3/STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).</p>Fórmula:C30H33FN4O3SCor e Forma:SolidPeso molecular:548.67STAT3-IN-41
<p>STAT3-IN-41 (Compound 16) is a prodrug of compound 1. It gradually releases compound 1, which inhibits the STAT3 signaling pathway. STAT3-IN-41 exhibits antitumor activity against lung cancer, hepatocellular carcinoma, and pancreatic cancer.</p>Fórmula:C22H30F3NO7Cor e Forma:SolidPeso molecular:477.4715,15-DPP
CAS:<p>5,15-Diphenylporphyrin (5,15-DPP) is a selective STAT3-SH2 antagonist with IC 50s of 0.28 μM and 10 μM for STAT3 and STAT1, respectively [1].</p>Fórmula:C32H22N4Cor e Forma:SolidPeso molecular:462.54Itacitinib adipate
CAS:<p>Itacitinib adipate: oral JAK1 inhibitor, tested in phase II myelofibrosis trial.</p>Fórmula:C32H33F4N9O5Cor e Forma:SolidPeso molecular:699.66AK-1690
CAS:<p>AK-1690 is a potent and selective STAT6 PROTAC degrader that induces degradation of STAT6 proteins in cells and depletes STAT6 proteins in mouse tissues.</p>Fórmula:C51H56F2N5O11PSPureza:99.95%Cor e Forma:SolidPeso molecular:1016.05Ilunocitinib
CAS:<p>Ilunocitinib is a non-selective and orally active Janus kinase (JAK) inhibitor for pruritus and atopic dermatitis caused by atopic dermatitis in dogs.</p>Fórmula:C17H17N7O2SPureza:99.88%Cor e Forma:SolidPeso molecular:383.43CHZ868
CAS:<p>CHZ868 is a type II JAK inhibitor with potential antitumor activity that reverses the persistence of type I JAK inhibitors and can be used to study leukemia.</p>Fórmula:C22H19F2N5O2Pureza:99.38%Cor e Forma:SolidPeso molecular:423.42Ifidancitinib
CAS:<p>Ifidancitinib (ATI-50002) is a JAK kinase 1/3 inhibitor used to study autoimmune diseases.</p>Fórmula:C20H18FN5O3Pureza:98.05%Cor e Forma:SolidPeso molecular:395.39Atinvicitinib
CAS:<p>Atinvicitinib, a selective JAK1 inhibitor, blocks cytokine signaling, modulating itch, allergy, and inflammatory responses, immune and therapeutic studies.</p>Fórmula:C16H17FN6O3Pureza:99.36%Cor e Forma:SolidPeso molecular:360.35Pim-1/2 kinase inhibitor 1
CAS:<p>Orally active Pim-1/2 inhibitor blocks kinase phosphorylation; used in prostate cancer research.</p>Fórmula:C11H9NO3SPureza:99.78%Cor e Forma:SolidPeso molecular:235.26SD-436
CAS:<p>SD-436 is a selective and highly efficient STAT3 PROTAC degrader (DC50 = 0.5 μM), with an IC50 of 19 nM for STAT3, significantly higher than for STAT1/4/5/6. SD-436 depletes STAT3 and induces tumour regression in mouse leukaemia and lymphoma xenograft models.</p>Fórmula:C58H62F4N9O14PSPureza:99.34%Cor e Forma:SolidPeso molecular:1248.2DTP3
CAS:<p>DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.</p>Fórmula:C26H35N7O5Cor e Forma:SolidPeso molecular:525.6WP1066
CAS:<p>WP1066 is a inhibitor of JAK2 (IC50: 2.30 μM) and STAT3 (IC50: 2.43 μM) in HEL cells; shows activity to JAK2, STAT3/5, and ERK1/2, not JAK1 and JAK3.</p>Fórmula:C17H14BrN3OPureza:98.92% - 99.73%Cor e Forma:SolidPeso molecular:356.22TP-3654
CAS:<p>TP-3654 is a second-generation Pim kinase inhibitor (Ki values against Pim-1/3: 5/42 nM).</p>Fórmula:C22H25F3N4OPureza:99.8% - 99.95%Cor e Forma:SolidPeso molecular:418.46Cucurbitacin I
CAS:<p>Cucurbitacin I (JSI-124), a natural compound, is a selective inhibitor of JAK2/STAT3 with anti-cancer activity.</p>Fórmula:C30H42O7Pureza:96.69% - 99.8%Cor e Forma:SolidPeso molecular:514.65XL019
CAS:<p>XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, 100 fold selectivity over JAK1.</p>Fórmula:C25H28N6O2Pureza:99.19%Cor e Forma:SolidPeso molecular:444.53TCS-PIM-1-4a
CAS:<p>SMI-4a, a Pim inhibitor, activates AMPK, halts mTORC1, and kills various myeloid/lymphoid cells (IC50=0.8-40μM).</p>Fórmula:C11H6F3NO2SPureza:99.89%Cor e Forma:SolidPeso molecular:273.23Quercetagetin
CAS:<p>Quercetagetin, a flavonoid from Citrus unshiu, inhibits pim-1 kinase (IC50: 0.34 μM), cell-permeable.</p>Fórmula:C15H10O8Pureza:99.65% - 99.91%Cor e Forma:SolidPeso molecular:318.24HODHBt
CAS:<p>HODHBt is a STAT5-SUMO protein-protein interaction inhibitor.</p>Fórmula:C7H5N3O2Pureza:99.45% - 99.95%Cor e Forma:Off-White To Yellow SolidPeso molecular:163.13Napabucasin
CAS:<p>Napabucasin (BBI608) is an orally available Stat3 and Y cell stemness inhibitor.</p>Fórmula:C14H8O4Pureza:98.43% - 99.85%Cor e Forma:SolidPeso molecular:240.21SHR0302
CAS:<p>SHR0302 (ARQ252) is a JAK inhibitor that binds JAK1 with stronger affinity than others (Selectivity for JAK1 is more than 10 times for JAK2, 77 times for JAK3,</p>Fórmula:C18H22N8O2SPureza:99.11%Cor e Forma:SolidPeso molecular:414.48ZM39923 hydrochloride
CAS:<p>ZM39923 hydrochloride (JAK3 Inhibitor IV) is an JAK1/3 inhibitor, almost no activity to JAK2 and modestly potent to EGFR; also is sensitive to transglutaminase.</p>Fórmula:C23H25NO·HClPureza:98.05%Cor e Forma:SolidPeso molecular:367.91Peficitinib
CAS:<p>Peficitinib (ASP015K) (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.</p>Fórmula:C18H22N4O2Pureza:98.67% - 99.4%Cor e Forma:SolidPeso molecular:326.39BD750
CAS:<p>BD750 is an effective immunosuppressant and a JAK3/STAT5 inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation(IC50 of 1.5 μM and 1.1 μM in</p>Fórmula:C14H13N3OSPureza:99.02%Cor e Forma:SolidPeso molecular:271.34Protosappanin A
CAS:<p>Protosappanin A combats brain inflammation, suppresses rat heart transplant rejection, fights MRSA, and inhibits HIV with a 12.6 uM IC50.</p>Fórmula:C15H12O5Pureza:99.42% - 99.82%Cor e Forma:SolidPeso molecular:272.25AG490
CAS:<p>AG490 inhibits EGFR (0.1 μM IC50), 135x > selective than ErbB2, blocks JAK2, spares Lyn, Lck, Syk, Btk, Src.</p>Fórmula:C17H14N2O3Pureza:98.6% - 99.39%Cor e Forma:Yellow SolidPeso molecular:294.3BMS-911543
CAS:<p>BMS-911543 is a potent and selective inhibitor of JAK2 with IC50 of 1.1 nM, ~350-, 75- and 65-fold selective to JAK1, JAK3 and TYK2, respectively. Phase 1/2.</p>Fórmula:C23H28N8OPureza:97.69% - 99.98%Cor e Forma:SolidPeso molecular:432.52FM-381
CAS:<p>FM381, a JAK3 inhibitor with 127 pM IC50, is 410-3600x more selective over JAK1/2/TYK2.</p>Fórmula:C24H24N6O2Pureza:98.44%Cor e Forma:SolidPeso molecular:428.49Deucravacitinib
CAS:<p>Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable, allosteric TYK2 inhibitor.Cost-effective and quality-assured.</p>Fórmula:C20H19D3N8O3Pureza:98.52% - >99.99%Cor e Forma:SolidPeso molecular:425.46Momelotinib
CAS:<p>Momelotinib (LM-1149), an oral JAK1/2 inhibitor with IC50s 11/18 nM, blocks ATP binding, disrupting JAK-STAT pathway and reducing tumor growth.</p>Fórmula:C23H22N6O2Pureza:97.47% - 99.56%Cor e Forma:SolidPeso molecular:414.46RO495
CAS:<p>RO495 (CS-2667), a potent inhibitor of TYK2, inhibits TYK2 with IC50 of 1.5nM as tested in cell-based pharmacological assays</p>Fórmula:C17H14Cl2N6OPureza:97.94%Cor e Forma:SolidPeso molecular:389.24(Z)-LFM-A13
CAS:<p>(Z)-LFM-A13(IC50=2.5 μM), a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and IRK.</p>Fórmula:C11H8Br2N2O2Pureza:99.88%Cor e Forma:SolidPeso molecular:360AT9283
CAS:<p>AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).</p>Fórmula:C19H23N7O2Pureza:99.83% - 99.98%Cor e Forma:SolidPeso molecular:381.43Pim1/AKK1-IN-1
CAS:<p>Pim1/AKK1-IN-1: LKB1/AAK1 inhibitor with Kd 35/53/75/380 nM for Pim1/AKK1/MST2/LKB1, also targets MPSK1, TNIK.</p>Fórmula:C20H13N5OPureza:97.03% - 98.69%Cor e Forma:SolidPeso molecular:339.35CEP-33779
CAS:<p>CEP-33779 is a novel and selective inhibitor of JAK2 with an IC50 of 1.8±0.6 nM.</p>Fórmula:C24H26N6O2SPureza:98.24% - ≥95%Cor e Forma:SolidPeso molecular:462.57Pacritinib
CAS:<p>Pacritinib (SB1518) (SB1518) is an effective and specific inhibitor of JAK2 and FLT3 (IC50: 23/22 nM, in cell-free assays).</p>Fórmula:C28H32N4O3Pureza:99.25% - 99.49%Cor e Forma:SolidPeso molecular:472.58Baricitinib phosphate
CAS:<p>Baricitinib phosphate (INCB028050) is a selective orally bioavailable JAK1/JAK2 inhibitor.</p>Fórmula:C16H20N7O6PSPureza:99.4% - 99.82%Cor e Forma:SolidPeso molecular:469.41Momelotinib HCl
CAS:<p>Momelotinib HCl is a JAK1/2 inhibitor, reducing anemia in myelofibrosis (MF) patients.</p>Fórmula:C23H24Cl2N6O2Cor e Forma:SolidPeso molecular:487.38SMI-16a
CAS:<p>SMI-16a (PIM1/2 Kinase Inhibitor VI) , a cell-permeable thiazolidinedione compound, acts as an effective, ATP-competitive inhibitor against Pim-1/2 kinases (</p>Fórmula:C13H13NO3SPureza:99.99%Cor e Forma:SolidPeso molecular:263.31Gandotinib
CAS:<p>LY2784544(Gandotinib (LY2784544)) is a potent JAK2 inhibitor (IC50: 3 nM), effective in JAK2V617F(Ki: 0.245 nM).</p>Fórmula:C23H25ClFN7OPureza:99.33% - 99.86%Cor e Forma:SolidPeso molecular:469.94Filgotinib
CAS:<p>Filgotinib (GLPG0634) is a selective JAK1 inhibitor. The IC50 values against JAK1, JAK2, JAK3, and TYK2 are 10 nM, 28 nM, 810 nM, and 116 nM, respectively.</p>Fórmula:C21H23N5O3SPureza:98.03% - ≥95%Cor e Forma:SolidPeso molecular:425.52,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide
CAS:<p>2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide (GDC046), a potent lead analog, has good kinase selectivity and physicochemical properties.</p>Fórmula:C16H13Cl2N3O2Pureza:98.77%Cor e Forma:SolidPeso molecular:350.2JAK-IN-5 hydrochloride
CAS:<p>JAK-IN-5 hydrochloride is a JAK inhibitor [1].</p>Fórmula:C27H32ClFN6OCor e Forma:SolidPeso molecular:511.03AZD-1480
CAS:<p>AZD1480: JAK2 inhibitor, IC50 0.26 nM; selective vs Tyk2, JAK3; less on JAK1. Used in solid tumors, PPV, PMF, ET trials.</p>Fórmula:C14H14ClFN8Pureza:98.25% - 99.47%Cor e Forma:SolidPeso molecular:348.77Oclacitinib
CAS:<p>Oclacitinib (PF-03394197)(PF03394197) is a potent and selective JAKs inhibitor with IC50 of 10-99 nM; not inhibit a panel of 38 non-JAK kinases (IC50 's > 1000</p>Fórmula:C15H23N5O2SPureza:98% - 98.45%Cor e Forma:White To Off-White SolidPeso molecular:337.44Fedratinib
CAS:<p>Fedratinib (TG-101348) (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent activity against JAK3.</p>Fórmula:C27H36N6O3SPureza:97.31% - 99.96%Cor e Forma:SolidPeso molecular:524.68Tofacitinib Citrate
CAS:<p>Tofacitinib Citrate (CP-690550 citrate) is a a potent, cell-permeable inhibitor of JAK1/2/3 (IC50s: 1/20/112 nM).</p>Fórmula:C22H28N6O8Pureza:99.19% - 99.75%Cor e Forma:SolidPeso molecular:504.49(Z)-SMI-4a
CAS:<p>(Z)-SMI-4a (TCS PIM-1 4a) is a selective ATP-competitive Pim-1 kinase inhibitor with an IC50 of 21 nM.</p>Fórmula:C11H6F3NO2SPureza:97.66% - 99.93%Cor e Forma:SolidPeso molecular:273.23Oclacitinib maleate
CAS:<p>Oclacitinib maleate is a selective JAK inhibitor (IC50: 10-99 nM; JAK1 cytokines: 36-249 nM), with no effect on 38 non-JAK kinases.</p>Fórmula:C15H23N5O2S·C4H4O4Pureza:99.17%Cor e Forma:SolidPeso molecular:453.51Ruxolitinib (S enantiomer)
CAS:<p>Ruxolitinib S enantiomer (INCB18424) is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective JAK1/2 inhibitor.</p>Fórmula:C17H18N6Pureza:99.37% - 99.79%Cor e Forma:SolidPeso molecular:306.36HJ-PI01
CAS:<p>HJ-PI01 (HJ-PI01) is a Pim-2 inhibitor. HJ-PI01 (HJ-PI01) induces apoptosis and autophagic cell death in triple-negative human breast cancer.</p>Fórmula:C14H11NO2Pureza:98.92%Cor e Forma:SolidPeso molecular:225.24SAR-20347
CAS:<p>SAR-20347 is an inhibitor of TYK2, JAK1/2/3 (IC50: 0.6/23/26/41 nM).</p>Fórmula:C21H18ClFN4O4Pureza:98.99% - 99.77%Cor e Forma:SolidPeso molecular:444.84Fosifidancitinib
CAS:<p>Fosifidancitinib is a potent inhibitor of JAK 1 and JAK 3.</p>Fórmula:C21H21FN5O7PPureza:99.54%Cor e Forma:SolidPeso molecular:505.39Solcitinib
CAS:<p>Solcitinib (GLPG-0778), a JAK1 inhibitor, may treat psoriasis, ulcerative colitis, and lupus.</p>Fórmula:C22H23N5O2Pureza:99.61% - 99.82%Cor e Forma:SolidPeso molecular:389.45Ruxolitinib
CAS:<p>Ruxolitinib (INCB018424) is a JAK1/2 inhibitor (IC50=3.3/2.8 nM) that is potent and selective.</p>Fórmula:C17H18N6Pureza:99.4% - >99.99%Cor e Forma:SolidPeso molecular:306.36Ritlecitinib
CAS:<p>Ritlecitinib (PF-06651600) is an orally available, selective JAK3 inhibitor and does not affect the activity of JAK1/2.Cost-effective and quality-assured.</p>Fórmula:C15H19N5OPureza:98.82% - 99.92%Cor e Forma:SolidPeso molecular:285.34PF-06651600 malonate
CAS:<p>PF-06651600 is a potent and selective JAK3 inhibitor.</p>Fórmula:C18H23N5O5Cor e Forma:SolidPeso molecular:389.41Tofacitinib
CAS:<p>Tofacitinib (Tasocitinib) is an orally Janus kinase inhibitor. Tofacitinib is used for the treatment of rheumatoid arthritis. Cost effective and quality assured.</p>Fórmula:C16H20N6OPureza:99% - >99.99%Cor e Forma:SolidPeso molecular:312.37Gusacitinib HCl
CAS:<p>Gusacitinib (ASN-002/EN-3351), a potent SYK/JAK inhibitor, has strong antitumor activity in various cancers.</p>Fórmula:C24H29ClN8O2Cor e Forma:SolidPeso molecular:497Itacitinib
CAS:<p>Itacitinib (INCB039110) is an orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1) with potential antineoplastic activity.</p>Fórmula:C26H23F4N9OPureza:96.4% - 99.5%Cor e Forma:SolidPeso molecular:553.51SGI-1776
CAS:<p>SGI-1776 (Pim-Kinase Inhibitor IX) has been used in trials studying the treatment of Prostate Cancer, Non-Hodgkins Lymphoma, and Relapsed/Refractory Leukemias.</p>Fórmula:C20H22F3N5OPureza:99.3% - >99.99%Cor e Forma:SolidPeso molecular:405.42WHI-P97
CAS:<p>WHI-P97 is a rationally designed potent inhibitor of JAK-3.</p>Fórmula:C16H13Br2N3O3Pureza:99.93%Cor e Forma:SolidPeso molecular:455.1Pyridone 6
CAS:<p>Pyridone 6, a selective JAK1/2/3 and Tyk2 inhibitor with IC50s: JAK1=15 nM, JAK2=1 nM, JAK3 (Ki=5 nM), Tyk2=1 nM; weakly binds other kinases (130 nM-10 μM).</p>Fórmula:C18H16FN3OPureza:97.1% - 98.74%Cor e Forma:SolidPeso molecular:309.34WHI-P97 HCl
<p>WHI-P97 HCl is a potent and selective JAK-3 inhibitor.</p>Fórmula:C16H14Br2ClN3O3Pureza:99.49%Cor e Forma:SolidPeso molecular:491.56TCS PIM-1 1
CAS:<p>TCS PIM-1 1 (SC 204330) is a potent ATP-competitive inhibitor of Pim-1 kinase with an IC50 of 50 nM, selective over MEK1/2 and Pim-2.</p>Fórmula:C18H11BrN2O2Pureza:97% - 97.98%Cor e Forma:SolidPeso molecular:367.2WHI-P154
CAS:<p>WHI-P154 (Jak3 inhibitor ii) is a potent JAK3 inhibitor.</p>Fórmula:C16H14BrN3O3Pureza:98% - 99.67%Cor e Forma:SolidPeso molecular:376.2SC99
CAS:<p>SC99 inhibits JAK2-STAT3, reducing STAT3 genes, platelet activity, and has anti-myeloma, anti-thrombotic effects.</p>Fórmula:C15H8Cl2FN3OPureza:99.56%Cor e Forma:SolidPeso molecular:336.15Ruxolitinib phosphate
CAS:<p>Ruxolitinib phosphate (INCB18424 phosphate) is a JAK1/2 inhibitor with IC50 of 3.3 nM/2.8 nM. Cost-effective and quality-assured.</p>Fórmula:C17H21N6O4PPureza:98% - >99.99%Cor e Forma:SolidPeso molecular:404.36GLPG0634 analog
CAS:<p>GLPG0634 analog (GLPG0634 analogue) is a specific JAK1 inhibitor with IC50 of 10/28/810/116 nM for JAK1/2/3 and TYK2, respectively.</p>Fórmula:C23H18N6O2Pureza:99.52% - >99.99%Cor e Forma:SolidPeso molecular:410.43Baricitinib
CAS:<p>Baricitinib (INCB028050) is an orally JAK1 and JAK2 inhibitor. Baricitinib has anti-inflammatory and anti-tumor activity. Cost-effective and quality-assured.</p>Fórmula:C16H17N7O2SPureza:99% - >99.99%Cor e Forma:SolidPeso molecular:371.42GDC-0214
CAS:<p>GDC-0214 is an inhaled small-molecule JAK1 inhibitor and reduces fractional exhaled nitric oxide (Feno).</p>Fórmula:C28H28ClF2N9O3Pureza:99.75%Cor e Forma:SolidPeso molecular:612.03Peramivir Trihydrate
CAS:<p>Peramivir Trihydrate (RWJ-270201) is a neuraminidase inhibitor (IC50: 0.09 nM) which prevents normal processing of virus particles such that virus particles are</p>Fórmula:C15H28N4O4·3H2OPureza:99.52% - ≥95%Cor e Forma:SolidPeso molecular:382.45TG101209
CAS:<p>TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.</p>Fórmula:C26H35N7O2SPureza:99% - >99.99%Cor e Forma:SolidPeso molecular:509.67NVP-BSK805 trihydrochloride
CAS:<p>NVP-BSK805 trihydrochloride inhibits JAK2 (0.48 nM IC50); also affects JAK1, JAK3, TYK2.</p>Fórmula:C27H31Cl3F2N6OCor e Forma:SolidPeso molecular:599.93(E/Z)-Zotiraciclib
CAS:<p>(E/Z)-Zotiraciclib ((E/Z)-TG02) inhibits CDK2, JAK2, and FLT3 effectively with IC50s of 13, 73, and 56 nM, respectively.</p>Fórmula:C23H24N4OPureza:97.75% - 99.92%Cor e Forma:SolidPeso molecular:372.46G5-7
CAS:<p>G5-7 is an oral JAK2 inhibitor targeting EGFR/STAT3 phosphorylation with potential for glioma research.</p>Fórmula:C22H19F2NO3Pureza:97.3%Cor e Forma:SolidPeso molecular:383.39RO8191
CAS:<p>RO8191 (CDM-3008) (CDM-3008) is an agonist of interferon (IFN) receptor.</p>Fórmula:C14H5F6N5OPureza:98% - 98.85%Cor e Forma:SolidPeso molecular:373.21Fedratinib hydrochloride hydrate
CAS:<p>Fedratinib hydrochloride hydrate (SAR 302503 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor.</p>Fórmula:C27H40Cl2N6O4SPureza:98.96% - 99.87%Cor e Forma:SolidPeso molecular:615.61Decernotinib
CAS:<p>Decernotinib (VRT-831509)(VX-509; VRT-831509) is a potent and selective Janus kinase 3 (JAK3) inhibitor with Ki of 2.5 nM; IC50 is 50-170 nM in cellular assays.</p>Fórmula:C18H19F3N6OPureza:99.28% - >99.99%Cor e Forma:SolidPeso molecular:392.38AMG-47a
CAS:<p>AMG-47a inhibits Lck, T cell growth, and degrades KRAS oncoprotein, affecting EGFP-KRASG12V but not EGFP.</p>Fórmula:C29H28F3N5O2Pureza:98%Cor e Forma:SolidPeso molecular:535.56JAK3-IN-6
CAS:<p>JAK3-IN-6 is irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC50 of 0.15 nM</p>Fórmula:C19H18N4O3Pureza:99.94% - 99.94%Cor e Forma:SolidPeso molecular:350.37Niclosamide sodium
CAS:<p>Niclosamide (BAY2353) sodium: oral antihelminthic, STAT3 inhibitor (IC50 0.25 μM), anti-cancer, and DNA replication blocker.</p>Fórmula:C13H7Cl2N2NaO4Cor e Forma:SolidPeso molecular:349.1RGB-286638 free base
CAS:<p>RGB-286638 free base inhibits CDKs (1-5 nM), weaker on CDK7/6.</p>Fórmula:C29H35N7O4Pureza:98% - 99.91%Cor e Forma:SolidPeso molecular:545.63FLLL32
CAS:<p>FLLL32 is an effective JAK2/STAT3 inhibitor (IC50 of <5 μM).</p>Fórmula:C28H32O6Pureza:97% - 97.90%Cor e Forma:SolidPeso molecular:464.55Abrocitinib
CAS:<p>Abrocitinib (PF-04965842) (PF-04965842) is a potent, specific and orally-active JAK1 inhibitor (IC50s: 29/803 nM for JAK1/2).</p>Fórmula:C14H21N5O2SPureza:99.09% - 99.91%Cor e Forma:SolidPeso molecular:323.41JANEX-1
CAS:<p>JANEX-1: cell-permeable, reversible Jak3 inhibitor (IC50: 78 μM), ATP-competitive, selective; weak on JAK1/2, Zap/Syk, SRC.</p>Fórmula:C16H15N3O3Pureza:98% - 99.81%Cor e Forma:SolidPeso molecular:297.31STAT5-IN-1
CAS:<p>STAT5-IN-1 (STAT5 Inhibitor) is a cell-permeable inhibitor which suppresses Stat5 via binding to the SH2 domain.</p>Fórmula:C16H11N3O3Pureza:99.44% - ≥95%Cor e Forma:SolidPeso molecular:293.28AZD1208
CAS:<p>AZD1208 is a novel, orally bioavailable, highly selective PIM kinase inhibitor with single nanomolar potency against all three PIM kinases.</p>Fórmula:C21H21N3O2SPureza:97.24% - 99.83%Cor e Forma:SolidPeso molecular:379.48Hispidulin
CAS:<p>Hispidulin, a natural flavone with a broad spectrum of biological activities, is a Pim-1 inhibitor (IC50: 2.71 μM).</p>Fórmula:C16H12O6Pureza:98.53% - 99.87%Cor e Forma:SolidPeso molecular:300.26Pacritinib hydrochloride
CAS:<p>Pacritinib HCl: strong JAK2/Wild-type & JAK2V617F inhibitor (IC50: 23/19 nM), used in AML & MF research.</p>Fórmula:C28H32N4O3·xClHCor e Forma:SolidBrevilin A
CAS:<p>Brevilin A, a sesquiterpene from Centipeda minima, hinders JAK and blocks STAT3 (IC50=10.6μM), inducing apoptosis and autophagy in cancer cells.</p>Fórmula:C20H26O5Pureza:99.97% - >99.99%Cor e Forma:SolidPeso molecular:346.42WDR5-0103 hydrochloride[890190-22-4(free base)]
<p>WDR5-0103 hydrochloride[890190-22-4(free base)] (WD-Repeat Protein 5-0103) is an effective and specific WD repeat-containing protein 5 (WDR5) antagonist (Kd:</p>Fórmula:C21H26ClN3O4Pureza:99.66%Cor e Forma:SolidPeso molecular:419.9Ritlecitinib tosylate
CAS:<p>Ritlecitinib (PF-06651600) is a potent, selective JAK3 inhibitor with proven in vivo efficacy, low clearance, and has undergone clinical trials.</p>Fórmula:C22H27N5O4SCor e Forma:SolidPeso molecular:457.549AZ960
CAS:<p>AZ960 is an effective ATP competitive JAK2 inhibitor (IC50/Ki: <3 nM and0.45 nM).</p>Fórmula:C18H16F2N6Pureza:96.02% - 98.51%Cor e Forma:SolidPeso molecular:354.36Cerdulatinib
CAS:<p>Cerdulatinib (PRT2070) is an novel oral dual Syk/JAK inhibitor.</p>Fórmula:C20H27N7O3SPureza:98.74% - 99.49%Cor e Forma:SolidPeso molecular:445.54Upadacitinib
CAS:<p>Upadacitinib (ABT-494), a selective JAK1 inhibitor, is researched for autoimmune diseases; IC50: 43 nM.</p>Fórmula:C17H19F3N6OPureza:98.96% - 99.94%Cor e Forma:SolidPeso molecular:380.37Atractylenolide I
CAS:<p>Atractylenolide-I reduces inflammation, improves sepsis, liver, and kidney function, and enhances EOC cell sensitivity to paclitaxel.</p>Fórmula:C15H18O2Pureza:97.55% - 99.92%Cor e Forma:SolidPeso molecular:230.3CX-6258 hydrochloride
CAS:<p>CX-6258 hydrochloride (Pim-Kinase Inhibitor X) is an effective, orally efficacious Pim1/2/3 kinase inhibitor (IC50: 5/25/16 nM).</p>Fórmula:C26H24ClN3O3·HClPureza:96.03% - 98.60%Cor e Forma:SolidPeso molecular:498.4Cerdulatinib hydrochloride
CAS:<p>Cerdulatinib hydrochloride is an oral tyrosine kinase inhibitor targeting JAK1/2/3, TYK2, Syk, and 19 others with IC50 < 200 nM.</p>Fórmula:C20H28ClN7O3SPureza:99.85%Cor e Forma:SolidPeso molecular:482GS-829845
CAS:<p>GS-829845 is a JAK1 inhibitor, the main component of the active metabolite of Filgotinib, which is approximately 10-fold less potent and has a longer half-life</p>Fórmula:C17H19N5O2SPureza:99.93%Cor e Forma:SolidPeso molecular:357.43Golotimod
CAS:<p>Golotimod (SCV 07) is an antimicrobial active dipeptide with immunomodulatory activity for the study of recurrent genital herpes simplex virus 2 infections.</p>Fórmula:C16H19N3O5Pureza:99.88% - 99.98%Cor e Forma:SolidPeso molecular:333.34NVP-BSK805
CAS:<p>NVP-BSK805 (BSK 805) is an ATP-competitive JAK2 inhibitor.</p>Fórmula:C27H28F2N6OPureza:98%Cor e Forma:SolidPeso molecular:490.55Solrikitug
CAS:<p>Solrikitug,Anti-CRLF2 humanized IgG1κ monoclonal antibody.</p>Pureza:95%Cor e Forma:LiquidTLC1566-0618
CAS:<p>TLC1566-0618 shows antitumor activity and targets stat.</p>Fórmula:C20H15NO3S3Pureza:98%Cor e Forma:SolidPeso molecular:413.53(3S,4S)-Tofacitinib
CAS:<p>(3S,4S)-Tofacitinib, a less active enantiomer of tofacitinib, is a Janus kinases inhibitor.</p>Fórmula:C16H20N6OPureza:98%Cor e Forma:SolidPeso molecular:312.37Golotimod TFA
CAS:<p>Golotimod TFA (SCV 07 TFA) is a dipeptide exhibiting immunomodulatory and antibacterial activity, alleviates radiation-induced oral mucositis.</p>Fórmula:C18H20F3N3O7Pureza:98%Cor e Forma:SoildPeso molecular:447.36ZM39923
CAS:<p>ZM39923 is a JAK3 inhibitor (pIC50: 7.1). ZM39923 also effectively inhibits tissue transglutaminase (IC50: 10 nM).</p>Fórmula:C23H25NOPureza:98%Cor e Forma:SolidPeso molecular:331.45SD-1029
CAS:<p>SD-1029 is a JAK2 inhibitor and a novel Stat3 activation inhibitor that inhibits Stat3 phosphorylation and JAK-STAT signaling.</p>Fórmula:C25H32Br2Cl2N2O3Cor e Forma:SolidPeso molecular:639.25K00135
CAS:<p>K00135 (IMIDAZOPYRIDAZIN 1) is a selective inhibitor of Pim kinases and can be used in studies about gastric cancer and antileukemic therapeutics.</p>Fórmula:C18H18N4OPureza:98.16%Cor e Forma:SolidPeso molecular:306.36JAK-IN-11
CAS:<p>JAK-IN-11 (R-348) is a potent and selective inhibitor of JAK, has the potential for the skin disorders treatment.</p>Fórmula:C23H22FN5O4SPureza:99.75%Cor e Forma:SolidPeso molecular:483.52CX-6258
CAS:<p>CX-6258 is an orally valid Pim 1/2/3 kinase(IC50=5 nM/25 nM/16 nM) inhibitor. It has good biological activity and kinase specificity.</p>Fórmula:C26H24ClN3O3Pureza:97.46%Cor e Forma:SolidPeso molecular:461.94JAK-IN-20
CAS:<p>JAK-IN-20: potent oral JAK1,2,3 inhibitor with IC50s 7, 5, 14 nM respectively, good pharmacokinetics, anti-inflammatory in vivo.</p>Fórmula:C28H30FN7O2Cor e Forma:SolidPeso molecular:515.58Niclosamide monohydrate
CAS:<p>Niclosamide Monohydrate is used for the treatment of most tapeworm infections by inhibiting DNA replication.</p>Fórmula:C13H10Cl2N2O5Pureza:98%Cor e Forma:SolidPeso molecular:345.14Peficitinib hydrochloride
CAS:<p>Peficitinib HCl (ASP015K) is an oral JAK inhibitor with IC50s: JAK1 (3.9 nM), JAK2 (5.0 nM), JAK3 (0.7 nM), Tyk2 (4.8 nM).</p>Fórmula:C18H23ClN4O2Cor e Forma:SolidPeso molecular:362.86TK4b
CAS:<p>TK4b, a JAK inhibitor, targets leukemia/lymphoid diseases, with IC50s: 18.42 nM (JAK3) & 19.40 nM (JAK2).</p>Fórmula:C21H22N2O2Cor e Forma:SolidPeso molecular:334.41TK4g
CAS:<p>TK4g, a potent JAK inhibitor, has IC50s of 12.61 nM (JAK2) & 15.80 nM (JAK3); promising for lymphoid diseases & leukemia research.</p>Fórmula:C19H19N3O4SCor e Forma:SolidPeso molecular:385.44JAK-2/3-IN-2
CAS:<p>JAK-2/3-IN-2 (Compound 3h) is a potent JAK2 & JAK3 inhibitor with IC50s of 23.85 nM (JAK2) & 18.9 nM (JAK3).</p>Fórmula:C19H19ClN2OSCor e Forma:SolidPeso molecular:358.89XZH-5
CAS:<p>XZH-5 is an inhibitor of STAT3.</p>Fórmula:C22H25F6N5O4Pureza:98%Cor e Forma:SolidPeso molecular:537.46JAK-IN-14
CAS:<p>JAK-IN-14 (compound 16) is a specific JAK1 inhibitor. It prevents JAK1 phosphorylation by binding to the active site of JAK in immune, inflammation and cancer.</p>Fórmula:C19H15FN4OPureza:98.27%Cor e Forma:SolidPeso molecular:334.35TyK2-IN-2
CAS:<p>TyK2-IN-2 is a selective inhibitor of TYK2 (IC50s: 7 nM, 0.1 μM, and 0.05 μM for TYK2 JH2, IL-23, and IFNα).</p>Fórmula:C16H18N6OPureza:98%Cor e Forma:SolidPeso molecular:310.35JAK-IN-18
CAS:<p>"JAK-IN-18: potent JAK inhibitor for eye, skin, respiratory disease research (WO2018204238A1, comp 1)."</p>Fórmula:C27H28F2N6O3Cor e Forma:SolidPeso molecular:522.55JAK3-IN-12
CAS:<p>JAK3-IN-12 (compound 15k) is a potent inhibitor of JAK3 (IC50: 9.5 nM) and can be used in the study of rheumatoid arthritis.</p>Fórmula:C19H19N5O4SCor e Forma:SolidPeso molecular:413.45Tyk2-IN-5
CAS:<p>Tyk2-IN-5 is a selective and orally active inhibitor of Tyk2 JH2 (Ki: 0.086 nM for Tyk2 JH2; IC50: 25 nM for IFNα).</p>Fórmula:C21H19FN8O2Pureza:98%Cor e Forma:SolidPeso molecular:434.43Tyk2-IN-7
CAS:<p>Tyk2-IN-7 is an inhibitor of TYK2 JH2, binds to the TYK2 JH2 domain (IC50: 0.00053 μM; Ki.app: 0.00007 μM).</p>Fórmula:C18H15D3N6O3SPureza:98%Cor e Forma:SolidPeso molecular:401.46MS-1020
CAS:<p>MS-1020 inhibits JAK3/STAT3, blocks active JAK3, suppresses JAK3/STAT5 signaling, and targets STAT3 in certain cells.</p>Fórmula:C21H18N2O3Pureza:98%Cor e Forma:SolidPeso molecular:346.381,2,3,4,5,6-Hexabromocyclohexane
CAS:<p>Inhibits JAK2 autophosphorylation; non-cytotoxic at 100μM; 1μM reduces activity by 50%, 50μM nearly abolishes it.</p>Fórmula:C6H6Br6Pureza:98%Cor e Forma:SolidPeso molecular:557.54OICR-0547
CAS:<p>OICR-0547 is an inactive derivative of OICR-9429 and is commonly used as a negative control for OICR-9429.</p>Fórmula:C28H29F3N4O4Pureza:98%Cor e Forma:SolidPeso molecular:542.55JAK3-IN-9
CAS:<p>JAK3-IN-9, potent JAK3 inhibitor, IC50 of 1.7 nM, highly selective, low toxicity, orally bioavailable, shows anti-arthritis activity.</p>Fórmula:C17H23N5O4SCor e Forma:SolidPeso molecular:393.46EP009
CAS:<p>EP009, a novel, selective, and orally active inhibitor of JAK3, induces therapeutic response in T-cell malignancies.</p>Fórmula:C14H24O2Cor e Forma:SolidPeso molecular:224.34INCB16562
CAS:<p>INCB16562: oral JAK1/2 inhibitor, halts IL-6/STAT3 in myeloma cells, boosts drug efficacy, stunts myeloma in mice.</p>Fórmula:C19H11Cl2N5Cor e Forma:SolidPeso molecular:380.23
![WDR5-0103 hydrochloride[890190-22-4(free base)]](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTM%2Fthumb-webp%2FT5140.webp&w=3840&q=75)
